iRhythm Holdings (IRTC) 주식 개요
디지털 헬스케어 기업인 아이리듬 홀딩스는 미국에서 부정맥 진단을 위한 외래 심장 모니터링 서비스를 제공하는 기기 기반 기술의 설계, 개발 및 상용화를 담당하고 있습니다. 자세히 보기
IRTC Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
iRhythm Holdings, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$125.25 |
| 52주 최고가 | US$212.00 |
| 52주 최저가 | US$100.85 |
| 베타 | 1.32 |
| 1개월 변동 | 14.70% |
| 3개월 변동 | 9.44% |
| 1년 변동 | -24.40% |
| 3년 변동 | 24.13% |
| 5년 변동 | 169.41% |
| IPO 이후 변동 | 380.81% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Aug 23
IRTC: VitalConnect Deal Will Reshape Cardiac Monitoring Platform By 2027
The analyst price target for iRhythm Holdings has been revised from $147 to $157 as analysts factor in recent Q2 sales and margin beats, updated guidance, and the announced VitalConnect acquisition into lower discount rate assumptions, higher projected profit margins, and a reduced future P/E multiple. Analyst Commentary Recent research on iRhythm Holdings shows a mixed but generally constructive stance, with several firms adjusting price targets following the Q2 report and the VitalConnect acquisition announcement.Seeking Alpha • Aug 21
iRhythm: The Algorithmic Margin Inflection Changes The Story
Summary iRhythm Technologies is evolving from a cardiac patch producer to a comprehensive cardiac monitoring platform, leveraging software and workflow integration for a competitive advantage. Q2 2026 marked a financial inflection: 20.1% revenue growth, 72.8% gross margin, and adjusted EBITDA margin expansion to 19.3%, with raised full-year guidance and record free cash flow. The ZEUS platform's FDA clearance enables significant margin leverage, reducing clinician review time by 50% and targeting $100 million in cost savings over five years. The VitalConnect acquisition expands IRTC into mobile cardiac telemetry and remote monitoring, supporting broader workflow capture and 2027 margin targets, but introduces integration and capital allocation risks. Read the full article on Seeking Alpha
내러티브 업데이트 • Aug 09
IRTC: VitalConnect Deal And Guidance Raise Will Reshape Earnings Power
Analysts have updated price targets for iRhythm Holdings following recent Q2 beat and raise commentary and revised models. The primary valuation framework has moved from a fair value of $229.49 to $200.00 as assumptions for discount rate, revenue growth, profit margin, and future P/E are refreshed.Recent updates
내러티브 업데이트 • Aug 23
IRTC: VitalConnect Deal Will Reshape Cardiac Monitoring Platform By 2027
The analyst price target for iRhythm Holdings has been revised from $147 to $157 as analysts factor in recent Q2 sales and margin beats, updated guidance, and the announced VitalConnect acquisition into lower discount rate assumptions, higher projected profit margins, and a reduced future P/E multiple. Analyst Commentary Recent research on iRhythm Holdings shows a mixed but generally constructive stance, with several firms adjusting price targets following the Q2 report and the VitalConnect acquisition announcement.Seeking Alpha • Aug 21
iRhythm: The Algorithmic Margin Inflection Changes The Story
Summary iRhythm Technologies is evolving from a cardiac patch producer to a comprehensive cardiac monitoring platform, leveraging software and workflow integration for a competitive advantage. Q2 2026 marked a financial inflection: 20.1% revenue growth, 72.8% gross margin, and adjusted EBITDA margin expansion to 19.3%, with raised full-year guidance and record free cash flow. The ZEUS platform's FDA clearance enables significant margin leverage, reducing clinician review time by 50% and targeting $100 million in cost savings over five years. The VitalConnect acquisition expands IRTC into mobile cardiac telemetry and remote monitoring, supporting broader workflow capture and 2027 margin targets, but introduces integration and capital allocation risks. Read the full article on Seeking Alpha내러티브 업데이트 • Aug 09
IRTC: VitalConnect Deal And Guidance Raise Will Reshape Earnings Power
Analysts have updated price targets for iRhythm Holdings following recent Q2 beat and raise commentary and revised models. The primary valuation framework has moved from a fair value of $229.49 to $200.00 as assumptions for discount rate, revenue growth, profit margin, and future P/E are refreshed.내러티브 업데이트 • Jul 06
IRTC: Reimbursement Policy Shift Will Reshape Earnings Power And Sentiment
For iRhythm Holdings, the analyst fair value estimate has shifted from about $254 to roughly $229, as analysts recalibrated models in light of corrected EPS forecasts and a broader reset in medtech valuation assumptions. Analyst Commentary Recent Street research around iRhythm Holdings shows a mix of recalibrated models and shifting price targets, as analysts factor in updated EPS calculations and a reset in medtech valuation assumptions.
내러티브 업데이트 • Jun 22
IRTC: Medtech Repricing And EPS Reset Will Support Future Upside Potential
Analysts have trimmed their price targets on iRhythm Holdings, with one moving from $180 to $152 and another from $225 to $180, citing updated EPS modeling and a reset of medtech valuations in light of sector wide concerns around product cycles, the Affordable Care Act and utilization trends, inflation, and capital flowing to data centers rather than healthcare. Analyst Commentary Recent research on iRhythm Holdings points to a mixed but engaged view from Wall Street, with valuation tweaks tied to detailed EPS modeling and sector wide medtech repricing rather than a simple change in stance on the underlying business.내러티브 업데이트 • Jun 06
IRTC: Medtech Reset And EPS Revisions Will Set Up Future Upside
Analysts have trimmed the iRhythm Holdings fair value estimate from $195.00 to about $178.93, reflecting a series of reduced Street price targets as models are updated for lower projected EPS and a reset in medtech valuations. Analyst Commentary Recent Street research on iRhythm Holdings shows a mix of optimism on the companys long term potential and caution around execution risks and sector level valuation resets.내러티브 업데이트 • Apr 30
IRTC: 2026 Guidance And DOJ Overhang Weakness Will Support Future Upside
Analysts have trimmed the blended fair value estimate for iRhythm Holdings by about $4.57 to $195.00. This reflects a series of recent price target reductions across the Street that center on sector wide multiple compression following Q4 updates and ongoing DOJ related headline risk.새로운 내러티브 • Apr 23
Long Term Cardiac Monitoring And AI Will Transform This Ambulatory Heart Care Leader
Catalysts About iRhythm Holdings iRhythm Holdings provides ambulatory cardiac monitoring services using wearable biosensors, AI tools and integrated clinical workflows. What are the underlying business or industry changes driving this perspective?내러티브 업데이트 • Apr 15
IRTC: 2026 Guidance And DOJ Overhang Weakness Will Drive Future Upside
Analysts have reduced their average price targets on iRhythm Holdings by about $12. This reflects slightly higher discount rate assumptions, modestly lower revenue growth expectations, and a lower future P/E multiple, even as longer term profit margin assumptions have increased.새로운 내러티브 • Apr 08
Primary Care And AI Headwinds Will Challenge Cardiac Monitoring Expansion Yet Ultimately Support Progress
Catalysts About iRhythm Holdings iRhythm Holdings provides ambulatory cardiac monitoring services built around its Zio biosensor platform and related analytics. What are the underlying business or industry changes driving this perspective?내러티브 업데이트 • Mar 31
IRTC: 2026 Guidance And DOJ Overhang Weakness Will Support Future Upside
iRhythm Holdings' updated fair value estimate edges up to about $211.43 per share, as analysts trim Street price targets into a tighter $184 to $225 range, citing sector wide multiple compression alongside Q4 execution and reiterated long term guidance. Analyst Commentary Research desks are consolidating around a tighter fair value band for iRhythm, with most recent moves involving modest price target trims that still sit above current Street lows.내러티브 업데이트 • Mar 16
IRTC: 2026 Guidance And Sector Reset Will Support Future Upside
iRhythm Holdings’ updated analyst price target of $211, slightly below the prior fair value estimate of about $212.87, reflects analysts fine tuning assumptions on discount rate, profit margins and future P/E multiples following recent sector wide target resets and mixed, yet generally supportive, research commentary on the company’s growth profile. Analyst Commentary Recent research on iRhythm Holdings shows a cluster of target price revisions, with most firms trimming their numbers but generally maintaining positive or neutral ratings.내러티브 업데이트 • Mar 02
IRTC: 2025 And 2026 Guidance Resilience Will Support Future Upside
Analysts have trimmed their average price target for iRhythm Holdings to about $213 from roughly $221 as they factor in lower valuation multiples across peers, while still highlighting recent revenue execution and margin improvement. Analyst Commentary Recent research on iRhythm shows a mix of optimism around execution and growth alongside a reset in valuation expectations, with several firms trimming price targets even as they acknowledge operational progress.내러티브 업데이트 • Feb 16
IRTC: 2025 Revenue Update And 2026 Outlook Will Support Future Upside
Analysts have nudged their price targets on iRhythm Holdings higher, with updates such as Wells Fargo moving to $225 from $220 and Goldman Sachs to $211 from $202. They cited the company’s 2025 revenue update above prior guidance and a 2026 growth outlook of 17% to 18% as key supports.내러티브 업데이트 • Feb 02
IRTC: 2025 Outlook And 2026 Expansion Will Support Future Market Share Gains
Analysts have raised their average price target for iRhythm by about $1, to roughly $221, citing the company's pre-announced 2025 revenue outlook above prior guidance and a 2026 revenue growth outlook of 17% to 18% as key supports for the updated view. Analyst Commentary Recent research on iRhythm points to a mix of optimism and caution, with price targets adjusted around the company’s updated 2025 and 2026 revenue outlook.내러티브 업데이트 • Jan 19
IRTC: Future Core Business Momentum Will Support Cardiac Monitoring Market Share Gains
Analysts have nudged their fair value estimate for iRhythm to $220.60 from $218.60, tying the modest move higher to higher modeled revenue growth, slightly different profit margin assumptions, and updated P/E expectations following recent price target increases from several firms and the company’s revised 2025 and 2026 revenue outlook. Analyst Commentary Street research on iRhythm has recently focused on updated revenue outlooks for 2025 and 2026 and how those feed into valuation frameworks and price targets.내러티브 업데이트 • Jan 04
IRTC: Future Core Business Momentum Will Drive Cardiac Monitoring Market Share Expansion
Analysts have nudged their blended fair value estimate for iRhythm Technologies modestly lower by about $2 to roughly $219, even as they lift published price targets into the low $200s. They cite a clean Q3 beat and raise, accelerating Zio AT adoption, and growing confidence in the durability of the company’s long term cardiac monitoring growth story.내러티브 업데이트 • Dec 15
IRTC: Future Core Business Momentum Will Drive Stronger Market Share Expansion
Analysts nudged their average price target on iRhythm Technologies slightly higher to about $221 from roughly $220, citing consistent beat and raise quarters, stronger than expected Q3 results, and growing confidence in the long term growth trajectory of the Zio cardiac monitoring portfolio. Analyst Commentary Street research remains firmly constructive on iRhythm Technologies, with recent notes highlighting both accelerating fundamentals and a still demanding valuation backdrop.내러티브 업데이트 • Nov 29
IRTC: Future Core Business Momentum Will Drive Stronger Market Share Gains
iRhythm Technologies' analyst price target was recently raised from $205 to $230, with analysts citing strong core business performance and increased confidence in the company's growth trajectory following a robust Q3 and elevated FY25 guidance. Analyst Commentary Recent analyst commentary highlights notable optimism around iRhythm Technologies’ execution and future prospects, but also flags several considerations that may temper enthusiasm.내러티브 업데이트 • Nov 15
IRTC: Future Channel Partnerships Will Drive Continued Market Share Gains
Analysts have raised their price target for iRhythm Technologies from approximately $193 to nearly $220 per share. They cite continued core business strength, expanding Zio AT adoption, and management’s increased confidence in future growth as key factors.분석 기사 • Nov 02
US$220 - That's What Analysts Think iRhythm Technologies, Inc. (NASDAQ:IRTC) Is Worth After These Results
iRhythm Technologies, Inc. ( NASDAQ:IRTC ) investors will be delighted, with the company turning in some strong numbers...내러티브 업데이트 • Oct 31
IRTC: Future Performance Will Reflect Both Product Momentum And Regulatory Uncertainty
Analysts have raised their price target for iRhythm Technologies from $180 to $205 per share. They cite strong recent results, expanding market share, and a positive outlook for the company's Zio Monitor platform as reasons for the increase.내러티브 업데이트 • Oct 17
Population Health And EHR Integration Will Redefine Remote Cardiac Care
iRhythm Technologies' analyst price target has increased from $186 to approximately $193. Analysts point to healthy revenue growth, expanded market reach, and positive physician feedback as drivers behind the upward revision.내러티브 업데이트 • Oct 03
Population Health And EHR Integration Will Redefine Remote Cardiac Care
The consensus analyst price target for iRhythm Technologies has increased modestly from $182.62 to $186.00. Analysts cite positive physician feedback and expected market expansion as key drivers for their outlook.분석 기사 • Aug 27
After Leaping 25% iRhythm Technologies, Inc. (NASDAQ:IRTC) Shares Are Not Flying Under The Radar
iRhythm Technologies, Inc. ( NASDAQ:IRTC ) shares have had a really impressive month, gaining 25% after a shaky period...내러티브 업데이트 • Aug 27
Population Health And EHR Integration Will Redefine Remote Cardiac Care
The consensus analyst price target for iRhythm Technologies has increased to $181.62, driven by a proposed CMS reimbursement boost, robust MyZio app growth, management’s confidence in market share gains, and progress on FDA remediation, reflecting improved fundamentals and growth visibility. Analyst Commentary Proposed CMS Physician Fee Schedule includes a low-single digit reimbursement boost for mobile cardiac telemetry, reversing previous larger cuts and providing greater payment visibility.분석 기사 • Aug 04
iRhythm Technologies, Inc. (NASDAQ:IRTC) Just Reported And Analysts Have Been Lifting Their Price Targets
A week ago, iRhythm Technologies, Inc. ( NASDAQ:IRTC ) came out with a strong set of second-quarter numbers that could...분석 기사 • Jul 21
Would iRhythm Technologies (NASDAQ:IRTC) Be Better Off With Less Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...새로운 내러티브 • May 26
Ambulatory Monitoring And Digital Health Will Transform Global Markets
Accelerated global adoption of Zio and digital health integration is expanding iRhythm's market reach, operational efficiency, and recurring revenue streams.분석 기사 • Apr 24
iRhythm Technologies, Inc.'s (NASDAQ:IRTC) Share Price Matching Investor Opinion
When you see that almost half of the companies in the Medical Equipment industry in the United States have...분석 기사 • Apr 03
Would iRhythm Technologies (NASDAQ:IRTC) Be Better Off With Less Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...분석 기사 • Feb 15
A Look At The Fair Value Of iRhythm Technologies, Inc. (NASDAQ:IRTC)
Key Insights iRhythm Technologies' estimated fair value is US$112 based on 2 Stage Free Cash Flow to Equity With US$112...분석 기사 • Jan 31
Is It Too Late To Consider Buying iRhythm Technologies, Inc. (NASDAQ:IRTC)?
While iRhythm Technologies, Inc. ( NASDAQ:IRTC ) might not have the largest market cap around , it saw a significant...분석 기사 • Jan 16
What You Can Learn From iRhythm Technologies, Inc.'s (NASDAQ:IRTC) P/S
You may think that with a price-to-sales (or "P/S") ratio of 5.8x iRhythm Technologies, Inc. ( NASDAQ:IRTC ) is a stock...주주 수익률
| IRTC | US Medical Equipment | US 시장 | |
|---|---|---|---|
| 7D | 7.1% | 1.5% | -1.2% |
| 1Y | -24.4% | -11.6% | 18.3% |
수익률 대 산업: IRTC은 지난 1년 동안 -11.6%의 수익을 기록한 US Medical Equipment 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: IRTC은 지난 1년 동안 18.3%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| IRTC volatility | |
|---|---|
| IRTC Average Weekly Movement | 7.2% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
안정적인 주가: IRTC는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: IRTC의 주간 변동성(7%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2006 | 2,400 | Quentin Blackford | www.irhythmtech.com |
디지털 헬스케어 회사인 아이리듬 홀딩스는 미국에서 부정맥 진단을 위한 외래 심장 모니터링 서비스를 제공하는 기기 기반 기술의 설계, 개발 및 상용화에 종사하고 있습니다. 이 회사는 장기 및 단기 연속 모니터링과 모바일 심장 원격 측정 모니터링 서비스를 포함한 Zio 외래 심장 모니터링 서비스를 제공합니다. 또한 심장의 전기 신호를 최대 14일 동안 지속적으로 기록하는 패치형 심전도 모니터로 구성된 처방 전용 원격 심전도(ECG) 모니터링 시스템인 Zio 모니터 시스템, 심장의 전기 신호를 최대 14일 동안 지속적으로 기록하는 Zio XT 패치로 구성된 처방 전용 원격 심전도 모니터링 시스템, 심전도 데이터의 캡처 및 분석을 지원하는 Zio ECG 활용 소프트웨어 시스템 등을 제공하고 있습니다.
iRhythm Holdings, Inc. 기초 지표 요약
| IRTC 기초 통계 | |
|---|---|
| 시가총액 | US$4.24b |
| 순이익 (TTM) | -US$13.95m |
| 매출 (TTM) | US$825.34m |
5.0x
주가매출비율(P/S)-296.0x
주가수익비율(P/E)IRTC는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| IRTC 손익계산서 (TTM) | |
|---|---|
| 매출 | US$825.34m |
| 매출원가 | US$235.60m |
| 총이익 | US$589.74m |
| 기타 비용 | US$603.68m |
| 순이익 | -US$13.95m |
최근 보고된 실적
Jun 30, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -0.42 |
| 총이익률 | 71.45% |
| 순이익률 | -1.69% |
| 부채/자본 비율 | 350.1% |
IRTC의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/08/24 22:32 |
| 종가 | 2026/08/24 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
iRhythm Holdings, Inc.는 26명의 분석가가 다루고 있습니다. 이 중 15명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| David Rescott | Baird |
| Joanne Wuensch | BMO Capital Markets Equity Research |
| Stephanie Elghazi | BofA Global Research |